Alemtuzumab for multiple sclerosis New
Alemtuzumab for multiple sclerosis New is a topic covered in the Cochrane Abstracts.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
"Alemtuzumab for Multiple Sclerosis New." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431525/0/Alemtuzumab_for_multiple_sclerosis_New. Accessed 23 March 2023.
Alemtuzumab for multiple sclerosis New. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431525/0/Alemtuzumab_for_multiple_sclerosis_New. Accessed March 23, 2023.
Alemtuzumab for multiple sclerosis New. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/431525/0/Alemtuzumab_for_multiple_sclerosis_New
Alemtuzumab for Multiple Sclerosis New [Internet]. In: Cochrane Abstracts. [cited 2023 March 23]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431525/0/Alemtuzumab_for_multiple_sclerosis_New.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - Alemtuzumab for multiple sclerosis New ID - 431525 BT - Cochrane Abstracts UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431525/0/Alemtuzumab_for_multiple_sclerosis_New DB - Evidence Central DP - Unbound Medicine ER -